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identified three genes that encode ion channels activated by biogenic amines: lgc-40, lgc-53 and lgc-55.
LGC-53 was activated with the highest efficacy by dopamine ( Fig. 1A) with an EC50 of 4.4 μM (Fig. 1B) .
LGC-55 was activated with the highest efficacy by tyramine with an EC50 of 6.0 μM (Fig. 1C and D) . LGC-40 was activated only by high concentrations of serotonin (EC50 = 905 μM) ( Fig. 1E and F). We tested whether other potential ligands could be more effective and found that choline and acetylcholine gated LGC-40 at lower concentrations (choline EC50 = 3.4 μM, acetylcholine EC50 = 87 μM) ( Fig. 1F) (11) . Compounds that block ion channels endogenous to Xenopus oocytes failed to block agonistevoked whole-cell currents in oocytes expressing LGC-40, LGC-53 and LGC-55, indicating that such endogenous channels did not mediate the agonist-evoked currents ( Figure S1 ).
Ligand binding by Cys-loop family ion channels is mediated by the amino-terminal extracellular domains of channel subunits (12) . We aligned the extracellular domain sequences of LGC-40, LGC-53 and LGC-55 with those of MOD-1 and 5-HT3 receptor subunits and of other Cys-loop family receptors but did not identify any amino acids that were conserved specifically among amine-gated channels ( Figure S2 ).
All previously characterized dopamine receptors are GPCRs (1) . We tested whether antagonists of G protein-coupled dopamine receptors can inhibit the LGC-53 dopamine-gated ion channel. Of seven antagonists tested ( Fig. 2A ), three acted with an IC50 of less than 100 μM: risperidone (IC50 = 40 μM), haloperidol (IC50 = 32 μM) and spiperone (IC50 = 38 μM) ( Fig. 2B -D) (10) . Risperidone, haloperidol and spiperone all are in clinical use as antipsychotics (1) . Since these drugs also block LGC-53, we suggest that some of their actions as therapeutics might be through inhibition of a yet-to-be-identified human dopamine receptor that, like LGC-53, is composed of Cys-loop family channel subunits.
We tested d-tubocurarine and atropine, antagonists of ionotropic and G protein-coupled acetylcholine receptors, respectively (1), and hemicholinium-3, a blocker of the high-affinity choline transporter (13) , for effects on choline-evoked currents in oocytes expressing LGC-40 ( Fig. 2F-G) .
LGC-40 currents were blocked by low concentrations of d-tubocurarine (IC50 = 8.3 μM) but were relatively insensitive to atropine ( Fig. 2F ). Hemicholinium-3 was the most effective antagonist of the LGC-40 channel, with an IC50 of 2.0 μM (Fig. 2G ). Thus, LGC-40 is sensitive both to a canonical antagonist of acetylcholine-gated ion channels as well as to an inhibitor of the high-affinity choline transporter.
The presumptive M2 regions, which are predicted to determine the ion selectivity of Cys-loop family ion channels, of LGC-40, LGC-53 and LGC-55 are more similar to the M2 regions of known chloride channels than to those of known cation channels ( Fig. 3A) (9, 12) . To test whether these receptors are chloride channels, we measured the reversal potentials of agonistevoked currents in Xenopus oocytes expressing LGC-40, LGC-53 and LGC-55 ( Fig. 3B through D). In solutions containing 96 mM Na + and 104 mM Cl -, ligand-evoked currents reversed at -23 to -26 mV, close to the reversal potential for chloride in Xenopus oocytes (14) . Replacement of sodium ions with N-methyl D-gluconate (NMDG) or choline did not alter the reversal potentials of the evoked currents. Replacement of chloride ions with gluconate shifted the reversal potentials positively by 17 to 31 mV ( Fig. 3B through D) (15) . These data indicate that LGC-40, LGC-53 and LGC-55 are chloride channels. The observed shift in reversal potential was less than predicted for channels that are perfectly selective for chloride over other anions (our unpublished observations); perhaps these channels might also pass the anions we used to replace chloride.
To identify biological functions of these amine-gated chloride channels, we isolated lgc-40, lgc-53 and lgc-55 deletion mutants ( Figure S3 ). lgc-55 mutants, which lack the tyramine-gated chloride channel, had a behavioral defect that indicated an in vivo function for this receptor in tyraminergic signaling. Tyramine from the RIM motor neurons suppresses small rapid head movements during touch-evoked locomotory reversals (16) . Animals lacking endogenous tyramine fail to suppress these head oscillations and exhibit the Sho phenotype (Suppression of head oscillations-defective), as do animals lacking the tyraminergic RIM motor neurons (16) ( Figure 4A ). Similarly, lgc-55 mutants continued to execute head movements during touch-evoked reversals (Fig. 4A ). The Sho phenotype of lgc-55 mutants was rescued by transgenes containing the lgc-55 cDNA fused to lgc-55 promoter sequences and by transgenes containing the lgc-55 cDNA fused to the unc-119 promoter, which drives expression broadly in the nervous system (17). To identify cells that express LGC-55, we created transgenic animals expressing GFP under the control of the lgc-55 promoter (17). We observed expression of this reporter transgene in head muscles and in the glia-like GLR cells, which are connected to the head muscles by gap junctions (18) , and weaker expression in many unidentified head neurons ( Figure 4B ). We also observed strong expression in the ALM and AVM mechanosensory neurons (data not shown). Expression of lgc-55 in muscles, including in head muscles, did not rescue the Sho phenotype of lgc-55 mutants (Fig. 4a ). Our findings suggest that LGC-55 can act in the GLR cells or neurons to control head movements and establish that the LGC-55 tyramine receptor functions in vivo in the tyraminergic control of head movements. No behavioral abnormalities were detected in mutants that carry deletions in lgc-40 and lgc-53 (19).
We conclude that including MOD-1 there exist in C. elegans at least four ligand-gated chloride channels that can be activated by biogenic amines. Our results indicate that ligand-gated chloride channels constitute a class of receptor for biogenic amines and that direct activation of membrane chloride conductances is a general mechanism of biogenic amine action in C. elegans. Biogenic amine-gated chloride channels might exist in the nervous systems of animals other than C. elegans and arthropods. In molluscs, synaptic dopamine rapidly activates a chloride conductance that is blocked by picrotoxin, an antagonist of ligand-gated chloride channels (20, 21, 22) . In the mammalian brain, histaminergic neurons project to the hypothalamus and use rapid inhibitory synaptic signals that are (i) not mediated by G protein signaling, (ii) are picrotoxin-sensitive and (iii) are mediated by chloride conductances (23) . The molecular identity of the histamine receptor in this synapse is not known, but the recent demonstration that GABA A receptor subunits can form histamine-gated chloride channels in vitro suggests that an ionotropic histamine receptor might contain known ligand-gated chloride channel subunits (24) . If direct activation of ligand-gated chloride channels is a mechanism of biogenic amine action in the mammalian brain, such receptors might be therapeutic targets, given the many links between aminergic signaling and psychiatric disorders (1, 25) .
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